Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Detection and Investigation of Eagle Effect Resistance to Vancomycin in Clostridium difficile With an ATP-Bioluminescence Assay.

Jarrad AM, Blaskovich MAT, Prasetyoputri A, Karoli T, Hansford KA, Cooper MA.

Front Microbiol. 2018 Jul 2;9:1420. doi: 10.3389/fmicb.2018.01420. eCollection 2018.

2.

In vitro susceptibility of genotypically distinct and clonal Clostridium difficile strains to oritavancin.

O'Connor R, Baines SD, Freeman J, Wilcox MH.

J Antimicrob Chemother. 2008 Oct;62(4):762-5. doi: 10.1093/jac/dkn276. Epub 2008 Jul 7.

PMID:
18606787
3.

In vitro susceptibility of Clostridium difficile to SMT19969 and comparators, as well as the killing kinetics and post-antibiotic effects of SMT19969 and comparators against C. difficile.

Corbett D, Wise A, Birchall S, Warn P, Baines SD, Crowther G, Freeman J, Chilton CH, Vernon J, Wilcox MH, Vickers RJ.

J Antimicrob Chemother. 2015;70(6):1751-6. doi: 10.1093/jac/dkv006. Epub 2015 Feb 3.

4.

In vitro activity of ramoplanin against Clostridium difficile, including strains with reduced susceptibility to vancomycin or with resistance to metronidazole.

Peláez T, Alcalá L, Alonso R, Martín-López A, García-Arias V, Marín M, Bouza E.

Antimicrob Agents Chemother. 2005 Mar;49(3):1157-9.

5.

Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: clinical and therapeutic implications.

Debast SB, Bauer MP, Sanders IM, Wilcox MH, Kuijper EJ; ECDIS Study Group.

J Antimicrob Chemother. 2013 Jun;68(6):1305-11. doi: 10.1093/jac/dkt013. Epub 2013 Feb 18.

PMID:
23420839
6.

Antibacterial activity of teicoplanin against Clostridium difficile.

Wongwanich S, Kusum M, Phan-Urai R.

Southeast Asian J Trop Med Public Health. 1996 Sep;27(3):606-9.

PMID:
9185278
7.

New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.

Zhanel GG, Calic D, Schweizer F, Zelenitsky S, Adam H, Lagacé-Wiens PR, Rubinstein E, Gin AS, Hoban DJ, Karlowsky JA.

Drugs. 2010 May 7;70(7):859-86. doi: 10.2165/11534440-000000000-00000. Review. Erratum in: Drugs. 2011 Mar 26;71(5):526.

PMID:
20426497
8.

Fidaxomicin: a macrocyclic antibiotic for the management of Clostridium difficile infection.

Sullivan KM, Spooner LM.

Ann Pharmacother. 2010 Feb;44(2):352-9. doi: 10.1345/aph.1M351. Epub 2010 Jan 13. Review.

PMID:
20071495
9.

Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection.

Goldstein EJ, Citron DM, Sears P, Babakhani F, Sambol SP, Gerding DN.

Antimicrob Agents Chemother. 2011 Nov;55(11):5194-9. doi: 10.1128/AAC.00625-11. Epub 2011 Aug 15.

10.

Fidaxomicin inhibits spore production in Clostridium difficile.

Babakhani F, Bouillaut L, Gomez A, Sears P, Nguyen L, Sonenshein AL.

Clin Infect Dis. 2012 Aug;55 Suppl 2:S162-9. doi: 10.1093/cid/cis453.

11.

Antimicrobial susceptibilities of Clostridium difficile isolated in Japan.

Kunishima H, Chiba J, Saito M, Honda Y, Kaku M.

J Infect Chemother. 2013 Apr;19(2):360-2. doi: 10.1007/s10156-013-0553-5. Epub 2013 Jan 22.

PMID:
23338015
12.

Fidaxomicin inhibits toxin production in Clostridium difficile.

Babakhani F, Bouillaut L, Sears P, Sims C, Gomez A, Sonenshein AL.

J Antimicrob Chemother. 2013 Mar;68(3):515-22. doi: 10.1093/jac/dks450. Epub 2012 Dec 2.

PMID:
23208832
13.

Pharmacodynamic studies of vancomycin, metronidazole and fusidic acid against Clostridium difficile.

Odenholt I, Walder M, Wullt M.

Chemotherapy. 2007;53(4):267-74. Epub 2007 Jun 25.

PMID:
17595541
14.

Fidaxomicin: in Clostridium difficile infection.

Duggan ST.

Drugs. 2011 Dec 24;71(18):2445-56. doi: 10.2165/11208220-000000000-00000.

PMID:
22141387
15.

In Vitro Activity of Tedizolid, Dalbavancin, and Ceftobiprole Against Clostridium difficile.

Binyamin D, Nitzan O, Azrad M, Hamo Z, Koren O, Peretz A.

Front Microbiol. 2018 Jun 11;9:1256. doi: 10.3389/fmicb.2018.01256. eCollection 2018.

16.

In vitro selection, via serial passage, of Clostridium difficile mutants with reduced susceptibility to fidaxomicin or vancomycin.

Leeds JA, Sachdeva M, Mullin S, Barnes SW, Ruzin A.

J Antimicrob Chemother. 2014 Jan;69(1):41-4. doi: 10.1093/jac/dkt302. Epub 2013 Jul 25.

PMID:
23887866
17.

Bactericidal activity of telavancin, vancomycin and metronidazole against Clostridium difficile.

Goldstein EJ, Citron DM, Tyrrell KL, Warren YA.

Anaerobe. 2010 Jun;16(3):220-2. doi: 10.1016/j.anaerobe.2009.12.002. Epub 2010 Jan 4.

PMID:
20044011
18.

Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections.

Lancaster JW, Matthews SJ.

Clin Ther. 2012 Jan;34(1):1-13. doi: 10.1016/j.clinthera.2011.12.003. Review.

PMID:
22284993
19.

Ambush of Clostridium difficile spores by ramoplanin: activity in an in vitro model.

Kraus CN, Lyerly MW, Carman RJ.

Antimicrob Agents Chemother. 2015 May;59(5):2525-30. doi: 10.1128/AAC.04853-14. Epub 2015 Feb 17.

20.

Effect of sub-MIC concentrations of metronidazole, vancomycin, clindamycin and linezolid on toxin gene transcription and production in Clostridium difficile.

Gerber M, Walch C, Löffler B, Tischendorf K, Reischl U, Ackermann G.

J Med Microbiol. 2008 Jun;57(Pt 6):776-83. doi: 10.1099/jmm.0.47739-0.

PMID:
18480337

Supplemental Content

Support Center